Seres Therap

Q2 FY2026 EarningsMCRB reported a significant Q2 FY26 beat on the bottom line, with a Net Income of $4.6M and Diluted EPS of $0.47, well above the consensus loss of -$20.5M and -$2.19 per share. This outperformance was primarily driven by a $25M one-time gain from the sale of the VOWST business to Nestlé. Revenue reached $0.74M, exceeding the $0.18M consensus due to higher-than-expected grant revenue. Management also announced aggressive cost-cutting measures, including the early termination of Cambridge facility leases, extending the cash runway into Q1 FY27.